About six months after coming out of stealth with $50 million in funding, Latent Labs has released a web-based AI model for programming biology.
Latent Labs‘ model has “achieved state-of-the-art in lab results for protein binding,” said Latent Labs CEO and founder Simon Kohl, a scientist who previously co-led DeepMind’s AlphaFold’s protein design team. State-of-the-art, or SOTA, is a term often used in the AI field that represents the industry’s best performance to date on a specific task.
“We have computational ways of assessing how good the designs are,” he told TechCrunch, adding that a high percentage of proteins the model creates will be viable when tested in a physical lab.
The company’s foundational biology model, known as LatentX, enables academic institutions, biotech startups, and pharmaceutical companies to design novel proteins directly in their browser.
LatentX goes beyond what’s found in nature, creating entirely new molecule designs with precise atomic structures. This approach can help develop new therapeutics at a much faster rate.
This ability to design entirely new proteins is what distinguishes LatentX from the AlphaFold, according to Kohl.
“AlphaFold is a model for protein structure prediction. So it allows you to visualize existing structures, but it doesn’t let you generate new proteins,” he said.
Disrupt 2026: The tech ecosystem, all in one room
Your next round. Your next hire. Your next breakout opportunity. Find it at TechCrunch Disrupt 2026, where 10,000+ founders, investors, and tech leaders gather for three days of 250+ tactical sessions, powerful introductions, and market-defining innovation. Register now to save up to $400.
Save up to $300 or 30% to TechCrunch Founder Summit
1,000+ founders and investors come together at TechCrunch Founder Summit 2026 for a full day focused on growth, execution, and real-world scaling. Learn from founders and investors who have shaped the industry. Connect with peers navigating similar growth stages. Walk away with tactics you can apply immediately
Offer ends March 13.
In contrast to AI-driven drug discovery companies like Xaira, Recursion, or DeepMind spinout Isomorphic Labs, which focus on developing proprietary medicines, Latent Labs’ business model involves licensing its model for use by external organizations.
“Not every company is in a position to build their own AI models, to have their own AI infrastructure, and to have their own AI teams,” Kohl said.
While LatentX is available for free, Kohl said the company intends to eventually charge for advanced features and capabilities as they’re introduced.
Other companies providing open sourced AI foundational models for drug discovery include Chai Discovery and EvolutionaryScale.
Latent Labs is backed by Radical Ventures, Sofinnova Partners, Google’s Chief Scientist Jeff Dean, Anthropic’s CEO Dario Amodei, and ElevenLabs CEO Mati Staniszewski.
